Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Titel:
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Auteur:
Hodi, Frank Stephen Chiarion-Sileni, Vanna Gonzalez, Rene Grob, Jean-Jacques Rutkowski, Piotr Cowey, Charles Lance Lao, Christopher D Schadendorf, Dirk Wagstaff, John Dummer, Reinhard Ferrucci, Pier Francesco Smylie, Michael Hill, Andrew Hogg, David Marquez-Rodas, Ivan Jiang, Joel Rizzo, Jasmine Larkin, James Wolchok, Jedd D